Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.
about
Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasisA matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironmentCorilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo.VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancerTargeting Bone Marrow to Potentiate the Anti-Tumor Effect of Tyrosine Kinase Inhibitor in Preclinical Rat Model of Human Glioblastoma.SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.Metastatic breast cancer: The Odyssey of personalization.Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.Cross-talk mechanism between endothelial cells and hepatocellular carcinoma cells via growth factors and integrin pathway promotes tumor angiogenesis and cell migration.Erythropoietin-Producing Hepatocellular A1 is an Independent Prognostic Factor for Gastric Cancer.Lysyl oxidase activates cancer stromal cells and promotes gastric cancer progression: quantum dot-based identification of biomarkers in cancer stromal cells.
P2860
Q33618582-4FDCFC35-E644-4F36-9269-97A84EFD5E81Q36572163-3B53F516-278D-49CB-B3F1-3133B677D8A2Q36734204-B6D52D2E-EFE8-400B-96FC-C38E3DC254ABQ37086056-1453C654-A924-4898-A480-AFECC2479EB0Q37095230-24627968-7F98-407B-AC9A-08B387F2B4CFQ37131869-F1D3CE66-D936-4A8F-A759-69E58F16759DQ38901163-3954C89D-9834-4236-8AD0-7FB83D2B8A92Q40384198-CD34FF9E-6D88-41A7-9E0C-1B9EF4C14247Q42378361-74B970CD-7E0C-44E1-B530-63540798836CQ44530924-93DF19A7-C656-4A4D-9BE4-4A3EAD4DA8A5Q49177437-6B49F9E6-7B4F-4886-A30E-A4329A20394A
P2860
Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.
@en
type
label
Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.
@en
prefLabel
Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.
@en
P2093
P2860
P50
P1433
P1476
Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.
@en
P2093
Antoine-Laurent Braccini
Christian Villanueva
Jérôme Barrière
Magali Lacroix-Triki
Marie-Ange Mouret-Reynier
Olivier Trédan
Philippe Barthélémy
Séverine Guiu
P2860
P2888
P304
P356
10.1007/S11523-014-0334-9
P577
2014-09-05T00:00:00Z
P5875
P6179
1023018580